We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 (MIDAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00993148
Recruitment Status : Completed
First Posted : October 12, 2009
Results First Posted : August 19, 2014
Last Update Posted : September 5, 2014
Sponsor:
Collaborators:
Information provided by (Responsible Party):

October 8, 2009
October 12, 2009
July 28, 2014
August 19, 2014
September 5, 2014
May 2010
April 2013   (Final data collection date for primary outcome measure)
Percentage of Participants With Plasma HIV-1 RNA >50 [ Time Frame: 24 weeks ]
Percentage of participants with confirmed plasma HIV-1 RNA > 50 copies/mL
Proportion of subjects with confirmed plasma HIV-1 RNA > 50 copies/mL [ Time Frame: 24 weeks ]
Complete list of historical versions of study NCT00993148 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Virologic Failure or Off Study Treatment Regimen [ Time Frame: 24 weeks ]
    Percentage of participants with virologic failure (confirmed plasma HIV-1 RNA > 50 copies/mL) or off study treatment regimen (composite end point)
  • Percentage of Participants With Plasma HIV-1 RNA >50 Copies/mL [ Time Frame: 48 weeks ]
    Percentage of participants with confirmed plasma HIV-1 RNA level >50 copies/mL
  • Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher [ Time Frame: 96 weeks ]
    Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen
  • Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES [ Time Frame: At study entry and at the time of virologic failure ]
  • Drug Adherence, Number of Participants With Missed Doses [ Time Frame: Week 24 ]
    Drug adherence, assessed as number of participants with missed doses over four-day recall
  • Trough Concentrations (Ctrough) of Maraviroc [ Time Frame: 24 hours ]
    Average trough concentration (Ctrough) of maraviroc
  • Median CD4 Count Change From Baseline [ Time Frame: 96 weeks ]
    Median changes from baseline in peripheral CD4+ T-cell count
  • Proportion of Participants With Plasma HIV-1 RNA >50 Copies/mL [ Time Frame: 96 weeks ]
    Proportion of participants with confirmed plasma HIV-1 RNA level >50 copies/mL
  • Proportion of subjects with virologic failure or off study treatment regimen (composite end point) [ Time Frame: 24 weeks ]
  • Dynamics of plasma HIV RNA decay measured on Days 7 and 14 in all subjects and additional sampling on days 2, 4, and 10 in a subset of 15 subjects [ Time Frame: Days 2,4,7,10,14 ]
  • Proportion of subjects with confirmed plasma HIV-1 RNA > 1000 copies/mL [ Time Frame: 12 weeks ]
  • Proportion of subjects with confirmed plasma HIV-1 RNA level confirmed >400 copies/mL [ Time Frame: 24 weeks ]
  • Proportion of subjects with confirmed plasma HIV-1 RNA level confirmed >400 copies/mL [ Time Frame: 48 weeks ]
  • Proportion of subjects with confirmed plasma HIV-1 RNA level >50 copies/mL [ Time Frame: 48 weeks ]
  • Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen [ Time Frame: Through 48 weeks ]
  • Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES [ Time Frame: At study entry and at the time of virologic failure ]
  • Evolution of CXCR4 and dual/mixed HIV during the early phase of viral decay [ Time Frame: 2 weeks ]
  • Drug adherence, assessed as number of missed doses over four-day recall [ Time Frame: Day 14 and weeks 4, 12, 24, and 48 ]
  • Trough concentrations (Cmin) of maraviroc and darunavir and associations of these PK parameters with efficacy outcome measures and adherence assessments [ Time Frame: Day 14 and weeks 4, 12, 24, and 48 and at virologic failure ]
  • Change in fasting lipids [ Time Frame: 48 weeks ]
  • Subject-specific changes from baseline (average of pre-entry and entry) in peripheral CD4+ T-cell count [ Time Frame: 48 weeks ]
  • Subject-specific changes from baseline (average of pre-entry and entry) in CD4+ and CD8+ T-cell subsets [ Time Frame: 48 weeks ]
  • Change in markers of inflammation, immune activation and coagulation [ Time Frame: 48 weeks ]
Not Provided
Not Provided
 
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
The objective of this study is to evaluate the safety and efficacy of a novel combination antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in treatment-naive patients infected with R5-tropic HIV-1. The hypothesis is that in treatment-naive subjects infected with R5-tropic HIV-1, combination antiretroviral therapy with maraviroc plus darunavir/ritonavir is well tolerated and efficacious.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV-1 Infection
  • HIV Infections
  • Drug: maraviroc
    150 mg tab by mouth once daily for 96 weeks
    Other Name: Selzentry
  • Drug: darunavir
    800 mg tab by mouth once daily for 96 weeks
    Other Name: Prezista
  • Drug: ritonavir
    100 mg capsule by mouth once daily for 96 weeks
    Other Name: norvir
Experimental: Maraviroc plus darunavir/ritonavir
Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
Interventions:
  • Drug: maraviroc
  • Drug: darunavir
  • Drug: ritonavir
Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
April 2013
April 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA any time prior to study entry
  • Plasma HIV-1 RNA 5, 000 to 500,000 copies/mL obtained within 90 days prior to study entry
  • Exclusive R5 tropism based on enhanced sensitivity Trofile assay done within 90 days prior to entry
  • CD4 cell count > 100 cells/mm3 within 90 days prior to study entry
  • HIV genotype (for RT and protease) performed at any time before study entry (Subjects with single or combination NNRTI or NRTI RAM(s) at screening are permitted)
  • ARV drug-naïve, defined as no previous ARV treatment at any time prior to study entry
  • Negative result from a hepatitis B surface antigen test performed within 90 days prior to study entry
  • Negative result from a hepatitis C antibody test performed within 90 days prior to study entry
  • Laboratory values obtained within 30 days prior to study entry:

    • ANC >=750/mm3
    • Hemoglobin >=10 g/dL
    • Platelets >=50,000/mm3
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase <=5 x ULN
    • Calculated creatinine clearance (CrCl) >=30 mL/min, as estimated by the Cockcroft-Gault equation*
  • Negative serum or urine pregnancy test within 48 hours prior to study entry for women with reproductive potential
  • If participating in sexual activity that could lead to pregnancy, the study subjects with reproductive potential must use one form of contraceptive while receiving protocol-specified medications and for 60 days after stopping the medications.
  • Men and women age >=18 years
  • Ability and willingness of subject or legal guardian/representative to provide informed consent

Exclusion Criteria:

  • Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry
  • Screening HIV genotype obtained any time prior to study entry with any DRV RAM (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V)
  • Treatment within 30 days prior to study entry with immune modulators such as systemic steroids, interleukins, interferons, granulocyte colony-stimulating factor (G-CSF), erythropoietin, or any investigational therapy. NOTE: Subjects receiving stable physiologic glucocorticoid doses (defined as prednisone ≤10 mg/day [or equivalent] as a stable or tapering dose) are permitted. Subjects receiving corticosteroids for acute therapy for PCP or asthma exacerbation, or receiving a short course (defined as ≤2 weeks of pharmacologic glucocorticoid therapy) are permitted
  • Breast-feeding
  • Requirement for any medication that is prohibited with a study medication
  • Known allergy/sensitivity to study drugs or their formulations. A history of sulfa allergy is not an exclusion
  • Active drug or alcohol use or dependence that could interfere with adherence to study requirements
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00993148
MIDAS
Yes
Not Provided
Not Provided
Babafemi Taiwo, Northwestern University
Northwestern University
  • Pfizer
  • Tibotec, Inc
Principal Investigator: Babafemi Taiwo, MD Northwestern University
Northwestern University
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP